Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Withdrawn) A pharmaceutical composition compromising a virally-safe plasma-derived Factor VIII obtained by filtering through a nanometric filter having a pore size of 13 nm to 25 nm, wherein the filtrate comprises the virally-safe plasma derived Factor VIII solution having a von Willebrand Factor (vWF) content of 15 % or less of decamers and higher multimers.
- 2. (Withdrawn) The pharmaceutical composition claim 1, wherein the titre reduction factor of a virus having a size of 24 to 30 nm is 4 log or more, 6 log as compared with the solution before filtration.
- 3. (Withdrawn) The pharmaceutical composition of claim 1, which is in the form of an injectable solution.
- 4. (Withdrawn) A method for testing the viral safety of a plasma-derived Factor VIII composition obtained by nanometric filtering, comprising the step of determining the residual content of high multimerisation vWF.
- 5. (Withdrawn) The method of claim 4, wherein a determination of the residual content of less than 15 % vWF decamers and higher multimers after nanometric filtration indicates that said composition is virally safe.

- 6. (Withdrawn) The method as of claim 5, wherein a determination of the residual content characterized in that the detection of less than 15 % vWF decamers and highermultimers is correlated with a reduction factor of virus titre of at least 4 log.
- 7. (Currently Amended) A method for preparing a virally safe Factor VIII solution, the method comprising:

filtering a solution comprising Factor VIII through nanometric filters having a pore size of 13 nm to 25 nm; and assaying the filtrate to determine the residual content of high multimerization von Willebrand Factor (vWF) vWF; and correlating the residual content of high multimerization vWF with viral safety.

- 8. (Previously Presented) The method of claim 7, wherein the step of assaying the filtrate includes verifying that the content of vWF decamers and higher multimers is 15 % or less.
- 9. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size diameter of 24 nm to 30 nm is 4 log or more, to about 6 log as compared with the solution before filtration.
- 10. (Canceled)
- 11. (Withdrawn) A pharmaceutical composition comprising virally-safe plasma-derived Factor VIII having a von Willebrand Factor (vWF) contents of about 15% of less or less decamers and higher multimers.

- 12. (Withdrawn) The pharmaceutical composition of claim 11 for use in treating diseases related to blood coagulation.
- 13. (Withdrawn) The pharmaceutical composition of claim 12 for use in treating haemophilia.
- 14. (Withdrawn) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log as compared with the solution before filtration.
- 15. (Withdrawn) The pharmaceutical composition of claim 1, wherein the titre reduction factor of a virus having a size of 24 nm to 30 nm is 6 log as compared with the solution before filtration.
- 16. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is 5 log ore or more, to about 6 log as compared with the solution before filtration.
- 17. (Currently Amended) The method of claim 7, wherein a vWF decamer and higher multimer content of 15 % or less indicates that the titre reduction factor of a virus having a size of 24 nm to 30 nm is 6 log ore more, to about 6 log as compared with the solution before filtration.

18. (Withdrawn) A pharmaceutical composition comprising a virally-safe
plasma-derived Factor VIII having a von Willebrand Factor content of 15% or less of decamers and higher mutimers.